Azurity Pharmaceuticals is cutting 75 employees effective Sept. 12 through Dec. 31 in Wilmington, Massachusetts, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. The specialty pharma company’s website lists that location as a manufacturing and operating facility.
All entries for: Cardiology
July 3, 2025
4D Molecular Therapeutics - Emeryville
Layoffs
Emeryville, CA
51-200 employees
California-based 4D Molecular Therapeutics is downsizing by 25% its current and planned roles in an effort to better realign its resources, the company announced on Wednesday. The layoffs will primarily affect staff supporting early-stage R&D activities and will allow the company to “drive late-stage execution,” as per the announcement.
Disease Area: Cardiology, Multiple, Respiratory Diseases
Drug Type: Biologic
July 1, 2025
Bristol Myers Squibb - Lawrenceville
Layoffs
Lawrenceville, NJ
10,001-50,000 employees
Bristol Myers Squibb continues to aim its cost-cutting measures at Lawrenceville, New Jersey, laying off 68 employees there, according to a Worker Adjustment and Retraining Notification notice. The pharma has now let go of 1,223 people in Lawrenceville since April 2024, including 874 team members this year. The latest cuts will occur in multiple waves starting Sept. 25 and end Jan. 15, 2026. BMS has its headquarters and a location housing its commercialization and late-stage development teams in Lawrenceville. It was not immediately clear if the latest layoffs affect both sites.
Disease Area: Cardiology, Hematology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
June 2, 2025
Stealth BioTherapeutics
Layoffs
Needham, MA
51-200 employees
To help direct resources toward a potential new drug application resubmission for Barth syndrome therapy elamipretide, Stealth BioTherapeutics has laid off 30% of its workforce, the company announced May 29. The Needham, Massachusetts–based biotech did not specify how many employees it let go, but its LinkedIn People page lists 65 associated members, meaning the cuts may have affected around 28 staffers.
Disease Area: Cardiology, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
May 15, 2025
Solid Biosciences
Negative Outlook
Charlestown, MA
51-200 employees
Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.
Disease Area: Cardiology, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
May 14, 2025
Bayer
Layoffs
Whippany, NJ
50,001+ employees
Bayer laid off some 2,000 employees in the first quarter of 2025, CEO Bill Anderson revealed in a media call May 13, alongside the presentation of the company’s first quarter earnings results.
Disease Area: Cardiology, Hematology, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
May 13, 2025
Lexeo Therapeutics
Layoffs
New York City, NY
51-200 employees
As part of its redeployment of about $20 million in capital from preclinical and noncardiac pipeline activities to its lead cardiac programs, Lexeo Therapeutics in April laid off roughly 15% of its employees, the company announced May 12. The New York–based biotech had 75 full-time employees as of March 31, according to an SEC filing, meaning the layoffs could affect around 11 employees.
Disease Area: Cardiology, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic
May 9, 2025
HCW Biologics
Neutral Outlook
Miramar, FL
1-50 employees
For example, the provisions related to the negotiation of selling prices of high- expenditure single-source drugs and biologics have been challenged in multiple lawsuits brought by pharmaceutical manufacturers. Thus, while it is unclear how the IRA will be implemented, it will likely have a significant impact on the pharmaceutical industry.
Disease Area: Cardiology, Chronic Disease, Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic
May 8, 2025
Edgewise Therapeutics
Negative Outlook
Boulder, CO
51-200 employees
The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved.
Disease Area: Cardiology, Chronic Disease, Multiple, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule